Harry Campbell
In 2010, some 1.6 million Americans were diagnosed with cancer. Each case is individual: Molecular characteristics may differentiate, say, one lung tumor from another. Long known for innovations in surgery and radiation, cancer researchers at Massachusetts General Hospital are now helping to pioneer treatments in which physicians base decisions on whether a tumor has a molecular bull’s-eye of genetic mutations that a new type of drug can target. MGH scientists showed that lung cancer treatments could be personalized in this way, and they’re finding that targeted therapies work for many melanomas and a growing roster of other cancers.
-
Aiming With Precision
Cancer treatment that zeroes in on specific genetic mutations is replacing the one-size-fits-all approach. // More -
A New Route for Clinical Trials
Researchers are using targeted clinical trials to test drugs on those who could most benefit from their application. // More -
A Match for Melanoma
Just two experimental pills daily helped a skin-cancer sufferer beat his survival odds. // More -
On the Trail of Circulating Tumor Cells
Researchers have a new tool for tracking metastasis: a device that plucks from a blood sample rare cells that can spread cancer throughout the body. // More -
Exposing Cancer’s Weakness
Through his work with genetic mutations, Daniel Haber has discovered that cancer is sometimes more vulnerable than once imagined. // More -
Hi-Def for Blood Vessels
At MGH, researchers have developed a technique that uses lasers to bring stunning new clarity to imaging. // More -
A Better Scan for Breast Cancer
A new technique, digital breast tomosynthesis, improves upon standard mammography. // More -
Prostate Cancer's Aftermath
A highly successful treatment for the disease brings a serious side effect: weakened bones. A new therapy, however, can help. // More
Video: Exposing Cancer's Weakness
Daniel Haber explains a new approach to cancer treatment.
// MORE
